Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214740) titled 'Study to Evaluate a Pegcetacoplan (Syfovre(R)) Prefilled Syringe' on Oct. 6.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Apellis Pharmaceuticals, Inc.

Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration

Intervention: Drug: APL-2, Pegcetacoplan

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 2025

Target Sample Size: 36

To know more, visit https://clinicaltrials.gov/study/NCT07214740

Published by HT Digital Content...